GAMPOD 50 DS

Cefpodoxime 50 mg (with wfi)

Remarkable Speed

• Greater in vitro activity against S.pneumoniae than cefaclor, cefuroxime, cefprozile or cefixime

Broad spectrum of antibacterial activity

• Extremely low mic values against common respiratory pathogens
• Empirical treatment for a wide range of community acquired infections

High Discipline

• Infants 2 months – children 12 years: 5 mg/kg every 12 hours

Favorable pharmacokinetic profile

• Excellent bacteriological & clinical efficacy in pediatric patients